Geode Capital Management
ATXS

Geode Capital Management’s Astria Therapeutics ATXS Stock Holding History

Geode Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,073,766
Closed -$14.1M – 4522
2025
Q4 		$14.1M Buy
1,073,766
+115,522
+12% +$1.38M ﹤0.01% 2208
2025
Q3 		$6.98M Sell
958,244
-5,694
-0.6% -$38.5K ﹤0.01% 2614
2025
Q2 		$5.17M Sell
963,938
-15,657
-2% -$75.9K ﹤0.01% 2710
2025
Q1 		$5.23M Buy
979,595
+29,198
+3% +$204K ﹤0.01% 2630
2024
Q4 		$8.5M Sell
950,397
-2,770
-0.3% -$29.4K ﹤0.01% 2470
2024
Q3 		$10.5M Sell
953,167
-60,423
-6% -$672K ﹤0.01% 2349
2024
Q2 		$9.23M Buy
1,013,590
+11,846
+1% +$116K ﹤0.01% 2371
2024
Q1 		$14.1M Buy
1,001,744
+304,529
+44% +$3.79M ﹤0.01% 2120
2023
Q4 		$5.36M Buy
697,215
+198,367
+40% +$1.1M ﹤0.01% 2669
2023
Q3 		$3.72M Buy
498,848
+30,870
+7% +$263K ﹤0.01% 2792
2023
Q2 		$3.9M Buy
467,978
+234,142
+100% +$2.7M ﹤0.01% 2824
2023
Q1 		$3.11M Buy
233,836
+110,143
+89% +$1.49M ﹤0.01% 2840
2022
Q4 		$1.84M Buy
123,693
+11,788
+11% +$122K ﹤0.01% 3084
2022
Q3 		$1.01M Buy
111,905
+27,709
+33% +$186K ﹤0.01% 3379
2022
Q2 		$252K Buy
84,196
+6,089
+8% +$27.3K ﹤0.01% 4130
2022
Q1 		$524K Buy
78,107
+13,093
+20% +$78K ﹤0.01% 3912
2021
Q4 		$350K Buy
65,014
+4,484
+7% +$29.5K ﹤0.01% 4223
2021
Q3 		$535K Buy
60,530
+29,063
+92% +$278K ﹤0.01% 4001
2021
Q2 		$398K Sell
31,467
-19,544
-38% -$254K ﹤0.01% 4041
2021
Q1 		$884K Buy
51,011
+9,869
+24% +$178K ﹤0.01% 3608
2020
Q4 		$528K Buy
41,142
+2,712
+7% +$48.3K ﹤0.01% 3574
2020
Q3 		$1.43M Buy
38,430
+163
+0.4% +$6.46K ﹤0.01% 3061
2020
Q2 		$1.48M Buy
38,267
+20,636
+117% +$735K ﹤0.01% 3002
2020
Q1 		$439K Buy
17,631
+4,207
+31% +$130K ﹤0.01% 3317
2019
Q4 		$476K Buy
13,424
+120
+0.9% +$3.78K ﹤0.01% 3515
2019
Q3 		$431K Hold
13,304
– – ﹤0.01% 3519
2019
Q2 		$644K Buy
13,304
+243
+2% +$11K ﹤0.01% 3378
2019
Q1 		$620K Buy
13,061
+8,220
+170% +$279K ﹤0.01% 3347
2018
Q4 		$126K Hold
4,841
– – ﹤0.01% 3819
2018
Q3 		$232K Hold
4,841
– – ﹤0.01% 3724
2018
Q2 		$278K Buy
4,841
+3,564
+279% +$329K ﹤0.01% 3623
2018
Q1 		$138K Hold
1,277
– – ﹤0.01% 3777
2017
Q4 		$114K Buy
1,277
+758
+146% +$89.2K ﹤0.01% 3788
2017
Q3 		$66K Hold
519
– – ﹤0.01% 3897
2017
Q2 		$44K Sell
519
-40
-7% -$3.33K ﹤0.01% 3976
2017
Q1 		$53K Buy
559
+5
+0.9% +$689 ﹤0.01% 3940
2016
Q4 		$119K Buy
554
+4
+0.7% +$979 ﹤0.01% 3751
2016
Q3 		$203K Buy
550
+1
+0.2% +$263 ﹤0.01% 3597
2016
Q2 		$121K Sell
549
-70
-11% -$21.1K ﹤0.01% 3744
2016
Q1 		$187 Sell
619
-1
-0.2% -$345 ﹤0.01% 3653
2015
Q4 		$295K Buy
620
+77
+14% +$37K ﹤0.01% 3514
2015
Q3 		$263K Buy
+543
New +$388K ﹤0.01% 3547

Geode Capital Management's ATXS Position: Q1 2026 in Review

Geode Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 1,073,766 shares — an estimated $14.1M sold.

Geode Capital Management first reported a position in ATXS in Q3 2015 and held it in 42 quarters. The position peaked at $14.1M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

  • Geode Capital Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Geode Capital Management sold 1,073,766 Astria Therapeutics shares in Q1 2026, an estimated $14.1M.
  • Geode Capital Management first reported a position in Astria Therapeutics in Q3 2015 and held it in 42 quarters.
  • Geode Capital Management's Astria Therapeutics position peaked at $14.1M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.